[go: up one dir, main page]

FR12C0052I1 - - Google Patents

Info

Publication number
FR12C0052I1
FR12C0052I1 FR12C0052C FR12C0052I1 FR 12C0052 I1 FR12C0052 I1 FR 12C0052I1 FR 12C0052 C FR12C0052 C FR 12C0052C FR 12C0052 I1 FR12C0052 I1 FR 12C0052I1
Authority
FR
France
Prior art keywords
administering
therapy
prevention
patient
rapid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0052(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR12C0052I1 publication Critical patent/FR12C0052I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR12C0052I2 publication Critical patent/FR12C0052I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR12C0052C 1999-09-03 2012-08-29 Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel Active FR12C0052I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15243599P 1999-09-03 1999-09-03
PCT/US2000/020788 WO2001017521A1 (fr) 1999-09-03 2000-08-22 Techniques d'utilisation d'inhibiteurs selectifs de recaptage de serotonine a apparition rapide pour traiter un dysfonctionnement sexuel

Publications (2)

Publication Number Publication Date
FR12C0052I1 true FR12C0052I1 (fr) 2012-05-10
FR12C0052I2 FR12C0052I2 (fr) 2013-08-16

Family

ID=22542905

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0052C Active FR12C0052I2 (fr) 1999-09-03 2012-08-29 Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel

Country Status (34)

Country Link
US (4) US7718705B1 (fr)
EP (3) EP1889614A3 (fr)
JP (1) JP3194734B2 (fr)
KR (1) KR100719977B1 (fr)
CN (1) CN1222283C (fr)
AT (1) ATE318135T1 (fr)
AU (1) AU762934B2 (fr)
BE (1) BE2012C040I2 (fr)
BG (1) BG65677B1 (fr)
BR (1) BR0014166A (fr)
CA (1) CA2383785C (fr)
CY (1) CY2012028I1 (fr)
CZ (1) CZ299712B6 (fr)
DE (2) DE60026146T2 (fr)
DK (1) DK1225881T3 (fr)
EA (1) EA004101B1 (fr)
EE (1) EE05315B1 (fr)
ES (2) ES2256032T3 (fr)
FR (1) FR12C0052I2 (fr)
HK (1) HK1047545B (fr)
HR (1) HRP20020189A2 (fr)
HU (1) HU229150B1 (fr)
IL (2) IL148159A0 (fr)
LU (1) LU92204I2 (fr)
MX (1) MXPA02001811A (fr)
MY (1) MY125490A (fr)
NO (2) NO330562B1 (fr)
NZ (1) NZ517038A (fr)
PL (1) PL211402B1 (fr)
SI (1) SI1225881T1 (fr)
TW (3) TWI312678B (fr)
UA (1) UA75580C2 (fr)
WO (1) WO2001017521A1 (fr)
ZA (1) ZA200201407B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
UA75580C2 (uk) * 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
EP1397126B9 (fr) 2001-03-16 2007-02-21 DMI Biosciences, Inc. Utilisation du tramadol pour retarder l'ejaculation
EE200300478A (et) 2001-03-29 2003-12-15 Bristol-Myers Squibb Company Tsüklopropüülindooli derivaadid kui selektiivsed serotoniini tagasihaarde inhibiitorid
CA2410966C (fr) * 2002-11-01 2005-11-22 Craig J. Hudson Accroissement des pulsions et des activites sexuelles a l'aide de tryptophane proteinique
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (de) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
DE102009058321A1 (de) * 2009-12-15 2011-06-16 Ratiopharm Gmbh Schmelztablette, enthaltend Dapoxetin
EP2591773A4 (fr) 2010-07-06 2014-11-26 Navipharm Co Ltd Composition pharmaceutique à libération prolongée et à action retardée comprenant de la dapoxétine pour administration orale
RU2463033C2 (ru) * 2010-08-06 2012-10-10 Василий Федорович Пятин Способ лечения преждевременной эякуляции
CN103100085A (zh) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 一种药物组合物
CN103130660B (zh) * 2011-11-25 2014-09-17 厦门福满药业有限公司 一类达泊西汀的酸式盐及其晶体,以及晶体的制备方法
WO2014042416A1 (fr) * 2012-09-13 2014-03-20 주식회사 씨티씨바이오 Composition orale contenant une base libre de dapoxétine
KR101432905B1 (ko) 2012-12-11 2014-08-21 가톨릭대학교 산학협력단 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CN103735525B (zh) * 2014-02-12 2015-05-06 江苏仁寿药业有限公司 一种达泊西汀片剂及制备方法
US20160045454A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (fr) * 2016-11-30 2018-06-07 Wang tian xin Méthodes thérapeutiques, formulations et formulations nutraceutiques
TR201620151A2 (en) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113181127A (zh) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀微丸片的制备方法
CN113143879A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀缓释片的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en) 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5151488A (en) * 1991-11-12 1992-09-29 The Mead Corporation Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5292962A (en) 1992-12-11 1994-03-08 Eli Lilly And Company Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2143049T3 (es) 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
CA2134038C (fr) 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (fr) 1995-02-10 1996-08-15 Eli Lilly And Company Procede de traitement ou de prevention de troubles psychiatriques
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
KR100274829B1 (ko) 1995-10-13 2000-12-15 페더 벨링 8-아자바이사이클로[3,2,1]-옥트-2-엔 유도체의 제조방법 및 용도
US5758911A (en) * 1996-02-07 1998-06-02 Northrop Grumman Corporation Linear motion wind driven power plant
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
PL337807A1 (en) 1997-07-01 2000-09-11 Pfizer Prod Inc Sertralin dosage formulation in the form of a gelatine-encapsulated solution
SK173299A3 (en) 1997-07-01 2000-11-07 Pfizer Prod Inc Delayed-release dosage forms of sertraline
FR2765483B1 (fr) 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
JP2002518331A (ja) 1998-06-19 2002-06-25 イーライ・リリー・アンド・カンパニー セロトニン再取り込みの阻害
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6150376A (en) 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
EA003990B1 (ru) 1998-10-13 2003-12-25 Пфайзер Продактс Инк. Пероральный концентрат сертралина
WO2000067729A1 (fr) * 1999-05-06 2000-11-16 Pentech Pharmaceuticals, Inc. Regime et necessaire destines a ameliorer l'ejaculation precoce
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
UA75580C2 (uk) * 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування

Also Published As

Publication number Publication date
TWI367751B (en) 2012-07-11
TW201018459A (en) 2010-05-16
FR12C0052I2 (fr) 2013-08-16
IL148159A0 (en) 2002-09-12
JP2001089394A (ja) 2001-04-03
CY2012028I2 (el) 2017-04-05
CN1387432A (zh) 2002-12-25
DE122009000036I1 (de) 2009-11-05
EE200200107A (et) 2003-04-15
NO330562B1 (no) 2011-05-16
NO20021035L (no) 2002-05-02
HU229150B1 (hu) 2013-09-30
JP3194734B2 (ja) 2001-08-06
CY2012028I1 (el) 2017-04-05
CA2383785C (fr) 2009-02-17
MXPA02001811A (es) 2002-08-06
WO2001017521A1 (fr) 2001-03-15
TWI312678B (en) 2009-08-01
SI1225881T1 (sl) 2006-06-30
CN1222283C (zh) 2005-10-12
AU762934B2 (en) 2003-07-10
US20140221497A1 (en) 2014-08-07
IL148159A (en) 2009-11-18
BG106461A (en) 2002-12-29
EP1225881B1 (fr) 2006-02-22
BG65677B1 (bg) 2009-06-30
ZA200201407B (en) 2003-07-30
KR100719977B1 (ko) 2007-05-21
AU6891100A (en) 2001-04-10
HK1091418A1 (en) 2007-01-19
UA75580C2 (uk) 2006-05-15
DE122009000036I2 (de) 2010-05-06
PL364924A1 (en) 2004-12-27
US7718705B1 (en) 2010-05-18
BR0014166A (pt) 2002-05-14
DE60026146T2 (de) 2006-08-17
CZ299712B6 (cs) 2008-10-29
HUP0202687A3 (en) 2006-03-28
EA200200324A1 (ru) 2002-08-29
NO20021035D0 (no) 2002-03-01
DK1225881T3 (da) 2006-06-12
ES2393582T3 (es) 2012-12-26
EP1889614A3 (fr) 2010-09-22
US20050261377A1 (en) 2005-11-24
NO2012015I2 (no) 2013-08-26
HRP20020189A2 (en) 2004-02-29
LU92204I2 (fr) 2013-07-23
DE60026146D1 (de) 2006-04-27
CZ2002784A3 (cs) 2002-09-11
NZ517038A (en) 2003-04-29
PL211402B1 (pl) 2012-05-31
EP1225881A1 (fr) 2002-07-31
EP1671628B1 (fr) 2012-10-03
EE05315B1 (et) 2010-08-16
EP1889614A2 (fr) 2008-02-20
EA004101B1 (ru) 2003-12-25
HK1047545A1 (en) 2003-02-28
KR20020025252A (ko) 2002-04-03
ATE318135T1 (de) 2006-03-15
US20050215617A1 (en) 2005-09-29
MY125490A (en) 2006-08-30
BE2012C040I2 (fr) 2019-10-16
CA2383785A1 (fr) 2001-03-15
HUP0202687A2 (hu) 2002-12-28
EP1671628A1 (fr) 2006-06-21
TW200524582A (en) 2005-08-01
HK1047545B (en) 2006-09-22
ES2256032T3 (es) 2006-07-16
NO2012015I1 (no) 2012-09-11

Similar Documents

Publication Publication Date Title
BE2012C040I2 (fr)
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
BR0316753A (pt) Método de tratamento para disfunção sexual
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d&#39;autres agents therapeutiques
ZA200109322B (en) A new use for deferiprone.
MXPA03004288A (es) Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
CY1118068T1 (el) Η χρηση δαποξετινης, ενος ταχειας-εναρξης επιλεκτικου αναστολεα εκ νεου αναληψης σepοτονινης για την θepαπευτικη αντιμετωπιση σεξουαλικης δυσλειτουργιας
PA8505301A1 (es) Metodo para tratar el mal de parkinson a traves de la administracion de ( - ) - 5 ceto-2-n- propilamino - tetrahidrotetralina
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
UY26405A1 (es) Método para tratar el mal de parkinson a través de la administración de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina.
ECSP993026A (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
ECSP003725A (es) Metodo para tratar el mal de parkinson a travez de la administracion de (-) -5- ceto-2-n, n-d1-n-propilamino-tetrahidrotetralina